Avacta Group Plc enters into a partnership and license agreement with LG Chem Life Sciences

  • Nov 13, 2019 GMT
  • Team Kalkine
  • Avacta Group Plc (AVCT) has released an update on the Affimer® therapeutics development partnership and license agreement.
  • The company to develop Affimer® therapeutics in various disease areas has collaborated with LG Chem Life Sciences and has also entered into a license agreement.
  • The company has effectively produced a large number of Affimer proteins that bind to the first drug target nominated by LG Chem Life Sciences, which has now expanded the collaboration by nominating the second and third drug targets.
  • The company is starting the discovery programmes for Affimer binders to those new targets.

With Bank of England reducing the interest rates to a historic low level, the spotlight is back on diverse investment opportunities. 

Amidst this, are you getting worried about these falling interest rates and wondering where to put your money?

Well! Team Kalkine has a solution for you. You still can earn a relatively stable income by putting money in the dividend-paying stocks.

We think it is the perfect time when you should start accumulating selective dividend stocks to beat the low-interest rates, while we provide a tailored offering in view of valuable stock opportunities and any dividend cut backs to be considered amid scenarios including a prolonged market meltdown.

To know more about these dividend stocks, click here

CLICK HERE FOR YOUR FREE REPORT!
   
x
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it. OK